Call for Abstract

11th Annual Biomarkers and Clinical Research Congress, will be organized around the theme “Bio Markers: Future of Medical Diagnosis and Treatment”

Biomarkers 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Clinical research biomarkers which are used for clinical purposes are known as clinical biomarkers. Clinical biomarkers provide active and influential way to understanding the scope of many diseases and epidemiology, random clinical trials, screening for drugs or disease diagnosis and prognosis. It is defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors that can extend the basic information about the underlying pathogenesis of diseases. The main researches in clinical biomarkers are done in the fields of drug discovery, pharmacogenomics, oncology, and disease diagnostics. Classes of Biomarkers in Clinical trials are segmented into Safety biomarkers & Efficacy biomarkers.

 

  • Track 1-1Health Biomarkers
  • Track 1-2Biomarkers Effectiveness
  • Track 1-3Clinical Trials of Biomarkers in Diagnostics
  • Track 1-4Clinical Trials of Biomarkers and Pharmacogenomics

Biomarkers and diagnostics play a crucial role in the outcomes and findings in clinical settings to enhance the quality of human health. Translational biomarkers and diagnostics can be applied in both preclinical and clinical setting. It should aim to translate the findings in fundamental research into medical practice and meaningful health outcomes. The characteristics for acceptable translational biomarkers and the various approaches to their selections including the latest trends and developments in translational biomarkers and diagnostics shall be discussed in this session. This session also discusses and reviews methods and requirements for qualification of translational biomarkers.

 

  • Track 2-1Biomarkers in dose selection
  • Track 2-2Evaluation of dose response
  • Track 2-3Dose selection in Biomarker
  • Track 2-4Biomarkers of Toxicity & Pharmacology

This biomarker conference throws light on the use of biomarkers in drug development which has emphasised the use of biomarkers as surrogate end points for effectiveness. Biomarkers enhances the understanding of the mechanism of action, enables the assessment of target engagement, facilitates early proof of dose focusing and increases the efficiency of early clinical development with improved quality of decision making, these concepts help in the drug discovery and development process.

 

  • Track 3-1Preclinical Research
  • Track 3-2Emergent Drug Development Approaches and Opportunities
  • Track 3-3Drug Development for Infectious Disease and Immuno Modulation
  • Track 3-4Fragment-Based Drug Discovery

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumour or a specific response of the body to presence of cancer. Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient’s cancer may or may not respond

  • Track 4-1To help analyze conditions, as on account of distinguishing beginning time malignant growths (Diagnostic)
  • Track 4-2To anticipate how well a patient will react to treatment (Predictive)

Cardiovascular disease (CVD) remains the leading cause of death globally. The identification of traditional risk factors such as age, hypercholesterolemia, hypertension, diabetes mellitus, and smoking has improved primary prevention of CVD. Cardiac markers are measured biomarkers to assess cardiac function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an elevation in the level of the cardiac marker. Cardiac biomarkers are elements that are released into the blood when the heart is damaged or strained. A cardiac marker is used in the identification and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have evolved as essential tools in cardiology in the last 50 years, that is, for primary and secondary prevention, the diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of the risk of heart failure.

  • Track 5-1Circulatory Biomarker
  • Track 5-2Biomarkers for Heart Failure & Acute Coronary Syndrome
  • Track 5-3Biomarkers for Metabolic Syndrome & Cardiovascular Risk

In spite of all the advances in neurology, there are serious deficiencies in our understanding of the pathomechanism of several neurological disorders as well as our ability to diagnose and treat these disorders. Biotechnologies are being increasingly applied in neurology to address some of these deficiencies. Novel biomarker identification for neurological disorders will address the current shortcomings in their diagnosis and therapeutics.

 

  • Track 6-1Biomarkers in Neuro-oncology Brain tumor & Brain damage
  • Track 6-2Biomarkers for early identification of Neurological disorders
  • Track 6-3Biomarkers in central nervous system diseases
  • Track 6-4Personalized medicine and diagnostic in Neuro science
  • Track 6-5cerebrospinal fluid biomarkers

In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy. Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same. Diagnostic tests and the biological biomarker (biomarkers) they measure are often classified based on the circumstances under which they are used. Biomarkers provide information about a patient at virtually every stage of care. They can help doctors evaluate the likelihood that a patient will develop a disease, diagnose a disorder, evaluate the severity of a disorder and/or its likely progression, determine optimal treatment strategies and monitor response to treatment.

 

  • Track 7-1Biomarkers discovery in Immunology
  • Track 7-2Challenges to biomarkers development in Immune system
  • Track 7-3Biomarkers discovery in Immunology
  • Track 7-4Biomarkers for Early Progressive Inflammatory & Immunological Diseases
  • Track 7-5Biomarkers of Disease Pathogenesis
  • Track 7-6Biomarkers under autoimmune system

Biomarkers focusing on two major areas of investigation: the early detection and prognosis. Early diagnosis and Prognostic Research encompasses the research addressing studies on the evaluation of medical tests, markers, prediction models and decision tools. Early diagnosis of cancer generally increases the chances for successful treatment by focusing on detecting symptomatic patients as early as possible. Delays in accessing cancer care are common with late-stage presentation, particularly in lower resource settings and vulnerable populations. The consequences of delayed or inaccessible cancer care are lower likelihood of survival, greater morbidity of treatment and higher costs of care, resulting in avoidable deaths and disability from cancer. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings.

 

  • Track 8-1Precision medicine
  • Track 8-2CRISPR
  • Track 8-3Genetic Testing
  • Track 8-4Gene Therapy

Biomarkers play an important role in prognosis and diagnosis of various cardiovascular and neurological diseases. The diseases which are deadly from ages has a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics methods and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis. These biomarkers are also used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, cardiovascular diseases, Huntington's disease, Neurodegenerative diseases, Diabetes and Behcet’s disease.

 

  • Track 9-1Cancer Stem Cell Therapy
  • Track 9-2Cancer Gene Therapy
  • Track 9-3Tumor Metabolism

Identification and validation of discovered gene or protein-based, network or dynamic network biomarkers with human diseases, patient phenotypes, or clinical applications, and accelerate the development of human disease-specific biomarkers for the early diagnosis, monitoring, evaluation, and prediction of diseases. Conditions including cancers, cardiovascular and metabolic diseases will be the focus of study. This section will promote the innovation and development of disease-specific biomarkers by integrating multidisciplinary aspects of science.

 

  • Track 10-1Autoimmune disease
  • Track 10-2Cardiovascular disease
  • Track 10-3Neurological disorder
  • Track 10-4Immunological disorder

Biomarkers have been classified based on the epidemiological investigations exposure to disease & biomarkers of disease which are also used in the investigation of the natural history and prognosis of a disease. In addition to the factors between exposure and disease, biomarkers have the potential to identify the earliest events in the natural history, reducing the rate of misclassification of both disease and exposure, leads to increase potential mechanisms related to the disease pathogenesis, accounting for some of the variability and effect modification of risk prediction. These epidemiological investigations are one of the reasons behind biomarkers to improve validity while reducing bias in the measurement of exposures (or risk factors) for neurological disease.

 

  • Track 11-1Principle of Recruitment and Ethical Concerns
  • Track 11-2IRB-approved recruitment protocol
  • Track 11-3Double-Blind Method

The biomarker congress focuses on the biomarker validation which is an open-ended process with open-ended evidentiary standards, where every potential application of the biomarker needs to be supported by independent studies and datasets. One aspect that has created a revolution in the concept of biomarker research and development is the Next Generation Sequencing which is versatile analysis tool for medical and biological research. Next Generation Sequencing technology refers to one high-throughput DNA sequencing method. In a single experiment, it can determine the sequence of the target gene or full genome with a total size of larger than millions of base pairs. Sequencing thousands of genes or even genomes in one experiment is consequently made possible using this NGS technology.

 

  • Track 12-1Biomarkers and endpoints for pain
  • Track 12-2Advancements in the technologies for discovery of biomarkers

Genomics and Clinical development promise the development of biomarkers to a state to predict the risk of individual disease that allows early detection of the disease and improves diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict the risk of diseases, to allow early detection of diseases, to improve the selection of treatment and to monitor the outcome of therapeutic interventions. The main objective of the Human Genome Project was the identification and development of such biomarkers for "personalized, preventive and predictive medicine".This clinical conference focuses on biomarkers incorporating in the gene level into earlier stages of the clinical trials which help to separate the patients and help in the development of the biomarker and in case of clinical development this incorporation serves in multiple ways from guiding dose selection to selecting the mode of action to providing the strategy to know about to whom the a particular biomarker can be used.

 

  • Track 13-1NGS for the discovery of Biomarkers
  • Track 13-2MicroRNA sequencing for the prediction of diseases
  • Track 13-3SNP as Biomarkers
  • Track 13-4Cytogenetic & Oxidative stress Biomarkers
  • Track 13-5Genetic-based Biomarkers and NGS in personalized care of Cancer

Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease. Because of normal clinical or biological variability, candidate biomarkers identified in the discovery stage need to be validated across a large number of samples. The challenge is to develop a fast, targeted analysis method capable of analysing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.

 

  • Track 14-1identification and initial biological, analytical and clinical validation of pain biomarkers

In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy. Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same. Diagnostic tests and the biological biomarker (biomarkers) they measure are often classified based on the circumstances under which they are used. Biomarkers provide information about a patient at virtually every stage of care. They can help doctors evaluate the likelihood that a patient will develop a disease, diagnose a disorder, evaluate the severity of a disorder and/or its likely progression, determine optimal treatment strategies and monitor response to treatment.

 

  • Track 15-1Imaging Technologies in Clinical Translation
  • Track 15-2Imaging Strategies and Molecular Profiling in Oncology
  • Track 15-3Imaging Techniques in Tissue Engineering
  • Track 15-4Imaging of Internal tissues and organs
  • Track 15-5Imaging in Neuroscience
  • Track 15-6Imaging biomarkers in Cardiovascular Systems and Musculoskeletal System

Biomedical Engineering is the science of application of engineering principles to the fields of biology and health care. Bioengineers work with doctors, therapists and researchers to implement systems, equipment and devices in order to solve clinical problems which focus on the advances that improve human health and health care at all levels. Clinical engineering is a special field within Biomedical engineering responsible primarily for applying and implementing medical technology to optimise healthcare delivery.

 

A key fixing in fruitful business is self-learning. Biomarkers-2019 plans to unite all current and growing bio-business people to share encounters and present new developments and difficulties inside the malignant growth network. Every year, over a million organizations work on the planet with about 5–10 of them being named high innovation organizations. Transforming thoughts into business adventures is precarious and the open door acknowledgment step is basic in new pursuit manifestations. This gestalt in the business visionary's view of the connection between the creation and last item is refined into a plan of action that depicts how the endeavour will profit or give a fitting come back to the potential financial specialists. Disease science is perplexing and quickly changing and requires specific information to comprehend the estimation of the advancement and its aggressive position in the business. This multi -day network wide gathering will be a very intelligent discussion which will get specialists zones extending from Biomarkers to flagging pathways to novel helpful ways to deal with the logical center point.